News Results for Puretech Health (PRTC)

Marjorie Scardino, Non Executive Director, bought 1,000 shares in the company on the 25th November 2020 at a price of $3.85. The Director now holds 788,710 shares. Story provided by...

Clinical-stage company Vedanta Biosciences has announced the appointment of Troy Ignelzi as an independent member to its board of directors. Vedanta is developing a new category of therapies for...

Robert Langer, Non Executive Director, has transferred out 308,876 shares in the company on the 28th October 2020 at a price of £0.00. The Director now holds 2,635,258 shares. Story provided by...

Christopher Viehbacher, Non Executive Director, bought 1,000 shares in the company on the 17th November 2020 at a price of $4.13. The Director now holds 1,029,516 shares. Story provided by...

Christopher Viehbacher, Non Executive Director, bought 5,000 shares in the company on the 17th November 2020 at a price of $4.14. The Director now holds 1,034,516 shares. Story provided by...

Christopher Viehbacher, Non Executive Director, bought 2,000 shares in the company on the 17th November 2020 at a price of $4.18. The Director now holds 1,041,516 shares. Story provided by...

Christopher Viehbacher, Non Executive Director, bought 5,000 shares in the company on the 17th November 2020 at a price of $4.15. The Director now holds 1,039,516 shares. Story provided by...

Christopher Viehbacher, Non Executive Director, bought 3,130 shares in the company on the 17th November 2020 at a price of $4.16. The Director now holds 1,045,646 shares. Story provided by...

Christopher Viehbacher, Non Executive Director, bought 1,000 shares in the company on the 17th November 2020 at a price of $4.16. The Director now holds 1,042,516 shares. Story provided by...

Christopher Viehbacher, Non Executive Director, bought 2,870 shares in the company on the 17th November 2020 at a price of $4.13. The Director now holds 1,028,516 shares. Story provided by...

Clinical-stage biotherapeutics company PureTech Health said it had completed a first-phase study for a potential treatment of conditions involving inflammation and fibrosis and disorders of...

Approaching midday the FTSE 100 was down 0.4% to 6,310.79, off its low point for the day and still on course for a strong week overall. Other European markets were in mildly positive territory...

UK markets have opened lower as Prime Minister Boris Johnson's senior adviser Dominic Cummings announced he is set to leave his role by Christmas. Meanwhile, in the US, election officials have...

Biotherapeutics company PureTech Health has said it expects trading of American depository shares (ADSs) of the company on Nasdaq to commence on Monday, 16 November 2020 under the ticker symbol...

PureTech Heath founded entity Vor has entered an exclusive licensing agreement with the National Cancer Institute. This agreement covers the group's intellectual property related to clinical...

John Lamattina, Non Executive Director, has transferred in 305,296 shares in the company on the 29th October 2020 at a price of £0.00. The Director now holds 1,512,733 shares. Story provided by...

John Lamattina, Non Executive Director, has transferred out 305,296 shares in the company on the 29th October 2020 at a price of £0.00. The Director now holds 1,207,437 shares. Story provided by...

Biotherapeutics company PureTech Health said it had filed a registration statement to list American depository shares on the Nasdaq stock market in the US. PureTech Health said the US listed was...

Biotherapeutics company PureTech Health welcomed news that founded entity Akili had presented positive data related to the trial of a digital-based treatment for attention-deficit/hyperactivity...

Biotherapeutics company PureTech Health said founded entity and oncology company Vor Biopharma had appointed Matthew R Patterson to its board. Patterson was co-founder of Audentes Therapeutics and...

Biotherapeutics company PureTech Health welcomed news that founded entity Alivio Therapeutics had awarded $3.3 million from US Department of Defense to advance a potential treatment for...

Clinical-stage biotherapeutics company PureTech Health said it had filed a registration statement with US regulators for a planned listing on the Nasdaq. The company said the US listing would not...

Biotherapeutics company PureTech Health said founded entity Vedanta Biosciences had appointed Jeffrey Silber as its chief medical officer. Silber had previously worked at Merck, AbbVie and EMD...

PureTech Health said founded entity Gelesis would deliver oral and poster presentations displaying efficacy data for a weight loss treatment at the European and International Congress on Obesity....

Biotechnology company PureTech Health generated $245m of cash in the first half of 2020 through the sales of stakes in subsidiaries. Its H1 income after tax of $123.7m was nearly four times the...

Biotherapeutics company PureTech Health said it had sold part of its stake in founded entity and central nervous system disorder focused Karuna Therapeutics for around $100m. PureTech said it...

Biotherapeutics company PureTech Health welcomed news that founded Entity Sonde Health had acquired voice-enabled survey and data acquisition platform NeuroLex Laboratories, for an undisclosed...

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 490p (from 450p). Story provided by StockMarketWire.com Broker Forecasts...

Biotherapeutics company PureTech Health welcomed news that founded entity Vor and oncology company Biopharma had appointed Christopher Slapak as its chief medical officer. Slapak previously led...

Biotherapeutics company PureTech Health welcomed news that founded entity Sonde Health had launched an app designed to detect respiratory diseases such as Covid-19 by monitoring voice recordings....

Clinical-stage biotherapeutics company PureTech Health welcomed news that founded entity Vor Biopharma had raised $110m of financing. Vor was developing engineered haematopoietic stem cell...

Biotherapeutics company PureTech Health welcomed news that founded entity Akili had received a CE mark for its digital-based treatment for attention deficit hyperactivity disorder. The EndeavorRx...

UK stocks opened substantially higher on Tuesday after the US Federal Reserve announced more fiscal stimulus to buffer the world's biggest economy from the Covid-19 crisis. At 0827, the benchmark...

Biotherapeutics company PureTech Health said founded entity Akili had received US regulatory approval for a digital-based treatment for attention-deficit/hyperactivity disorder. Clearance for use...

Biotherapeutics company PureTech Health has said that Follica, which it founded, has received positive feedback from the US Food and Drug Administration (FDA) as it prepares to advance its lead...

UK stocks rallied on Tuesday as hopes of an economic revival sparked by an easing Covid-19 lockdowns were tempered by persistent rioting in the US. At 16:30, the benchmark FTSE 100 index was 0.9%...

UK stocks held on to early gains at midday Tuesday as hopes of an economic revival sparked by an easing Covid-19 lockdowns were tempered by persistent rioting in the US. At 12:00, the benchmark...

Biotherapeutics company PureTech Health said its Gelesis unit, which it founded, had received approval to market a novel weight loss treatment in Europe. Gelesis had received a CE mark for the...

Clinical stage biotherapeutics company PureTech Health has announced plans to advance its product candidate LYT-100 (deupirfenidone) as a potential treatment for serious respiratory complications...

Dr John LaMattina, Non Executive Director, bought 6,700 shares in the company on the 20th May 2020 at a price of 250.00p. The Director now holds 1,512,283 shares. Story provided by...

Dr John LaMattina, Non Executive Director, bought 8,201 shares in the company on the 18th May 2020 at a price of 246.00p. The Director now holds 1,505,583 shares. NOTE: pca Story provided by...

Dr John LaMattina, Non Executive Director, bought 1,500 shares in the company on the 15th May 2020 at a price of 232.00p. The Director now holds 1,497,382 shares. NOTE: PCA Story provided by...

Dr John LaMattina, Non Executive Director, bought 1,000 shares in the company on the 14th May 2020 at a price of 220.00p. The Director now holds 1,496,332 shares. NOTE: average price. PCA Story...

Clinical stage biotherapeutics company PureTech Health has reported a strong capital base with $321.5m in pro-forma cash in its annual results to 31 December 2019 and confirmed the growth of its...

Serious disease focused PureTech Health said the first participant had been dosed in a clinical study of a treatment for lymphoedema and other fibrotic conditions. PureTech Health said there was...

PureTech Health welcomed news that affiliate company Akili had published positive trial results for a treatment for attention-deficit/hyperactivity disorder in The Lancet Digital Health journal....

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 450p (from 420p). Story provided by StockMarketWire.com Broker Forecasts...

Clinical stage biotech company, PureTech Health, has announced it has sold 2.1 million shares of its affiliate, Karuna Therapeutics. The cash sale has generated approximately $200 million which...

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and cut its price target to 420p (from 450p). Story provided by StockMarketWire.com Broker Forecasts...

Biotechnology company PureTech Health's affiliate Follica has announced topline results from its safety and efficacy optimisation study to treat hair loss in male androgenetic alopecia. In a...

PureTech Health said affiliate company Gelesis was partnering with US telehealth provider Ro to offer remote care dedicated to weight management. The pact would involve the distribution of...

Biotechnology company PureTech Health said affiliate Vedanta Biosciences had initiated a clinical study regarding an immuno-oncology candidate in patients with types of advanced or metastatic...

UK stocks traded slightly lower Monday, following the release of weak Chinese export data that offset positive sentiment inspired by strong US jobs numbers released Friday. At 16:00, the benchmark...

UK stocks opened a little lower on Monday following the release of weak Chinese export data that offset positive sentiment inspired by strong US jobs numbers released Friday. At 0844, the...

PureTech Health said affiliate company and obesity treatment developer Gelesis had raised $84.6m to fund the launch of a key product. The raising included equity funding of $63.4m, led by private...

Clinical stage biotechnology company PureTech Health has announced its affiliate, Vedanta Biosciences, has been awarded a $5.8m grant for its VE707 programme targeting multi-drug resistant...

Peel Hunt today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 460p (from 380p). Story provided by StockMarketWire.com Broker Forecasts data...

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 450p (from 300p). Story provided by StockMarketWire.com Broker Forecasts...

UK stocks finished lower on Monday after a report stoked fresh fears about a resolution to the US-China trade dispute that has hit global growth. A headwind for the FTSE 100 was a strengthening of...

PureTech Health noted that affiliate company Karuna Therapeutics met its primary goal in a clinical trial of a treatment of acute psychosis in patients with schizophrenia. The treatment, called,...

PureTech Health noted that independent affiliate resTORbio had announced disappointing data from a study evaluating the safety and efficacy of a treatment for clinically symptomatic respiratory...

PureTech Health affiliate Sonde Health has appointed David Liu as chief executive and a member of its board of directors. The appointment follows the recently announced $16m Series A financing...

Brain-gut axis treatment developer PureTech Health said it had acquired the remaining 10% of Ariya Therapeutics that it did not already own. The company had been renamed LYT and would its four...

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 347p (from 336p). Story provided by StockMarketWire.com Broker Forecasts...

Clinical stage biotechnology company PureTech Health booked a first-half loss after a gain in the value of its investments was offset by a higher tax charge and steeper R&D spending. Net...

Biopharmaceutical company PureTech Health said affiliate Vor Biopharma had appointed Robert Ang as its chief executive. Ang joined from Neon Therapeutics, where he served as chief business...

Peel Hunt today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 380p (from 344p). Story provided by StockMarketWire.com Broker Forecasts data...

PureTech Health said it had acquired a clinical-stage product candidate for the potential treatment of lymphatic and immunofibrotic diseases, including lymphedema. In preclinical studies, the...

Biopharmaceutical company PureTech Health said it was "exploring the potential" for a listing on the Nasdaq stock exchange in the United States. The US listing would be expected to include an...

PureTech Health said it had been issued with a patent in the US that supported an immuno-oncology product candidate. The US Patent and Trademark Office had issued US Patent No. 10,344,091 to...

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 336p (from 308p). Story provided by StockMarketWire.com Broker Forecasts...

PureTech Health, a biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced a new corporate headquarters and labs in Boston's...

PureTech Health said that affiliate Karuna Therapeutics had filed for a proposed initial public offering of shares in the US. The number of shares to be offered and the price range for the...

PureTech Health said affiliate Vor Biopharma had announced the publication of a paper in a scientific journal supporting its approach to treating cancer via engineered hematopoietic stem cells....

PureTech Health said affiliate Vedanta Biosciences had announced an $18.5m extension of a financing round, bringing the total for the round to $45.5m. The new investment came from JSR Corporation,...

Biopharmaceutical company PureTech Health has announced that its affiliate Gelesis has received a $10.6m grant to support the commercial manufacturing of its first product, Plenity. The company...

PureTech Health, which develops treatments for 'dysfunctions of the brain-immune-gut axis', booked an full-year loss as it ramped up R&D spending. Pre-tax losses for the year through December...

PureTech Health said affiliate Gelesis had received marketing clearance from the FDA for a weight management product. The orally-administered hydrogel was designed to absorb water and increase the...

Peel Hunt today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 344p (from 320p). Story provided by StockMarketWire.com Broker Forecasts data...

PureTech affiliate Sonde Health announced it had completed a $16m Series A financing round to advance Sonde's vocal biomarker technology. The proceeds from the financing would be used to progress...

PureTech Health said affiliate Karuna Therapeutics had completed a $68m financing round. The series B financing included the issuance of $5m in shares upon conversion of debt into equity....

Peel Hunt today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 320p (from 313p). Story provided by StockMarketWire.com Broker Forecasts data...

Jefferies International today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 255p (from 245p). Story provided by StockMarketWire.com Broker...

PureTech Health said its Vedanta Biosciences unit had commenced a clinical study of a treatment for the Clostridium difficile bowel infection. The phase-two study of the treatment, VE303, was...

PureTech Health noted that affiliate company Vedanta Biosciences had entered into a collaboration with Bristol-Myers Squibb. The companies had agreed to to evaluate Vedanta's microbiome-derived...

PureTech Health said subsidiary Vedanta Biosciences had released data showing that a product candidate had induced an anti-tumour response. The treatment, VE800, is an orally-administered, live...

PureTech Health said affiliate company Karuna Pharmaceuticals had started a key study for a treatment for psychosis in schizophrenia. The so-called Phase 2 study would test least product candidate...

The Vedanta Biosciences arm of biopharma company PureTech announced that preliminary results from its Phase 1a/1b clinical study of its live biotherapeutic product VE303 demonstrated safety,...

The FTSE 100 remained in the red after US President Donald Trump threatened to impose tariffs on all imports for China. The blue-chip index was 5.1 points lower at 7,678. Miners were among the...

The FTSE 100 struggled on Friday with earlier gains wiped out in late morning trading thanks to the broadcast of a news interview where Donald Trump threatened to put tariffs on all Chinese...

PureTech Health said it had entered into a multi-year collaboration with Roche to advance PureTech's milk-derived exosome platform technology. The technology would be applied to assist in the oral...

Jefferies International today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and set its price target at 245p. Story provided by StockMarketWire.com Broker Forecasts data...

Peel Hunt today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and set its price target at 313p. Story provided by StockMarketWire.com Broker Forecasts data provided by...

Biopharmaceutical group PureTech Health said annual operating losses deepened as revenue fell and it continued to study treatments for ADHD and obesity. The company is still in product development...

Commense, an affiliate of PureTech Health, announced the appointment of Edward J "Tad" Stewart as President and Chief Executive Officer. Mr Stewart will focus on advancing Commense's lead program...

Dr John LaMattina, Non Executive Director, bought 43,000 shares in the company on the 14th March 2018 at a price of 163.00p. The Director now holds 1,495,332 shares. NOTE: Connected Trust Story...

Dr Robert Langer, Non Executive Director, bought 4,300 shares in the company on the 13th March 2018 at a price of 162.00p. The Director now holds 2,944,134 shares. Story provided by...

Peel Hunt today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 313p (from 302p). Story provided by StockMarketWire.com

PureTech Health said affiliate company resTORbio has a priced its initial public offering on the Nasdaq exchange. Shares would be issued at an offer price of $15.00 each, resulting in gross...